Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
The role of topoisomerases in the replication of human adenovirus type 5 was investigated with topoisomerase inhibitors. Both topoisomerase I and topoisomerase II inhibitors blocked adenovirus replication when added at the time of infection. Both types of inhibitors induced strand cleavages at specific sites in the adenovirus early templates. The cleavage sites were mapped near the 5' and 3' ends of the genes transcribed early during infection. At late times after infection, camptothecin, a topoisomerase I inhibitor, inhibited adenovirus DNA replication and induced the formation of single- and double-stranded fragments with breakpoints located at defined regions of the viral genome. The topoisomerase II inhibitors, VP-16 (etoposide) and ellipticine, did not block adenovirus DNA replication and did not induce an appreciable amount of double-strand cleavages in the newly synthesized DNA. On the other hand, VP-16 promoted double-strand cleavages at specific sites of nonreplicating adenovirus DNA. The packaging of adenovirus DNA into virus particles, which contain supercoiled adenovirus DNA (M.-L. Wong and M.-T. Hsu, Nucleic Acids Res. 17:3535-3550, 1989), was inhibited by the topoisomerase II inhibitors. Transcription of adenovirus major late genes was inhibited by both topoisomerase I and topoisomerase II inhibitors. In addition, camptothecin caused a premature termination of major late transcription. Electron microscopic analysis showed that adenovirus templates late after infection were arranged in topologically constrained loop domains. Together, these data provide evidence for the requirement of topoisomerase activities in the replication, transcription, and packaging of the linear adenovirus genome.
Wong
M L
ML
Department of Microbiology, Mount Sinai School of Medicine of City University of New York, New York 10029-6574.
Hsu
M T
MT
D000260:Adenoviruses, Human / Q000187:drug effects / Q000235:genetics*; D000470:Alkaloids / Q000494:pharmacology*; D015139:Blotting, Southern; D002166:Camptothecin / Q000494:pharmacology*; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D004261:DNA Replication / Q000187:drug effects*; D004264:DNA Topoisomerases, Type I / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004279:DNA, Viral / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D003852:Deoxyribonucleoproteins / Q000648:ultrastructure; D015180:Electrophoresis, Gel, Two-Dimensional; D004591:Electrophoresis, Polyacrylamide Gel; D004611:Ellipticines / Q000494:pharmacology*; D005047:Etoposide / Q000494:pharmacology*; D006367:HeLa Cells / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D008854:Microscopy, Electron; D013698:Templates, Genetic; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014158:Transcription, Genetic / Q000187:drug effects*
D000470:Alkaloids; D004279:DNA, Viral; D003852:Deoxyribonucleoproteins; D004611:Ellipticines; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; C034192:ellipticine; D005047:Etoposide; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; D002166:Camptothecin